Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

By sjmartinez • August 31, 2023

Moser CB, Chew KW, Ritz J, Newell M, Javan AC, Eron JJ, Daar ES, Wohl DA, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S92-S100. doi: 10.1093/infdis/jiad209. PMID: 37650234.

Tags: adaptive platform trials, covid-19, Harbor UCLA, Infectious Diseases, pooled placebo, Publications, randomization

Inflammatory markers and calcification of coronary arteries, aorta and cardiac valves: Findings from the atherosclerosis risk in communities study

Avula V, Mok Y, Ejiri K, Van't Hof J, Whelton SP, Hoogeveen RC, Ballantyne CM, Budoff MJ, Blaha MJ, Matsushita K. Inflammatory markers and calcification[...]

Doxycycline Postexposure Prophylaxis for Bacterial STIs: Prescribing Patterns, Use, Short-term Outcomes Among 2083 Patients in a Los Angeles Federally Qualified Health Care Program, and Implications for Widespread Use

Osmundson J, Holloway IW, Macias Gil R, Jann JT, Hong C, Bolan RK. Doxycycline Postexposure Prophylaxis for Bacterial STIs: Prescribing Patterns, Use, Short-term Outcomes Among[...]

Characteristics of Virtual Pulmonary Rehabilitation Programs in the United States: Results from a National Electronic Survey

Moy ML, Corn J, Kizziar A, Kaye R, Dorney Koppel GA, Bhatt SP, Casaburi R, Desiato JT, Garvey C. Characteristics of Virtual Pulmonary Rehabilitation Programs[...]